✦ LIBER ✦

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin

✍ Scribed by Lanitis, T.; Cotté, F. E.; Gaudin, A. F.; Kachaner, I.; Kongnakorn, T.; Durand-Zaleski, I.

Book ID: 126967693
Publisher: Informa plc
Year: 2014
Tongue: English
Weight: 611 KB
Volume: 17
Category: Article
ISSN: 1369-6998
DOI: 10.3111/13696998.2014.923891

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Apixaban, Dabigatran, and Rivaroxaban Ve

Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis

✍ Rognoni, Carla; Marchetti, Monia; Quaglini, Silvana; Liberato, Nicola Lucio 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 332 KB

Economic Evaluation of Warfarin, Dabigat

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation

✍ Wisløff, Torbjørn; Hagen, Gunhild; Klemp, Marianne 📂 Article 📅 2014 🏛 Springer International Publishing AG 🌐 English ⚖ 765 KB

Comparative Effectiveness of Dabigatran,

Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation

✍ Pink, J. (author);Pirmohamed, M. (author);Hughes, D. A. (author) 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 781 KB

Comparative Effectiveness of Dabigatran,

Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation

✍ Pink, J. (author);Pirmohamed, M. (author);Hughes, D. A. (author) 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 781 KB

Meta-Analysis of Efficacy and Safety of

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation

✍ Corey S. Miller; Sonia M. Grandi; Avi Shimony; Kristian B. Filion; Mark J. Eisen 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 926 KB

Lifetime costs and life-years gained ass

Lifetime costs and life-years gained associated with apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation

✍ Harrington, A.R.; Armstrong, E.P.; Nolan, P.; Malone, D.C. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB